These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35241226)

  • 1. Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
    Farkouh ME; Stone GW; Lala A; Bagiella E; Moreno PR; Nadkarni GN; Ben-Yehuda O; Granada JF; Dressler O; Tinuoye EO; Granada C; Bustamante J; Peyra C; Godoy LC; Palacios IF; Fuster V
    J Am Coll Cardiol; 2022 Mar; 79(9):917-928. PubMed ID: 35241226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19.
    Stone GW; Farkouh ME; Lala A; Tinuoye E; Dressler O; Moreno PR; Palacios IF; Goodman SG; Esper RB; Abizaid A; Varade D; Betancur JF; Ricalde A; Payro G; Castellano JM; Hung IFN; Nadkarni GN; Giustino G; Godoy LC; Feinman J; Camaj A; Bienstock SW; Furtado RHM; Granada C; Bustamante J; Peyra C; Contreras J; Owen R; Bhatt DL; Pocock SJ; Fuster V;
    J Am Coll Cardiol; 2023 May; 81(18):1747-1762. PubMed ID: 36889611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
    Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
    Billett HH; Reyes-Gil M; Szymanski J; Ikemura K; Stahl LR; Lo Y; Rahman S; Gonzalez-Lugo JD; Kushnir M; Barouqa M; Golestaneh L; Bellin E
    Thromb Haemost; 2020 Dec; 120(12):1691-1699. PubMed ID: 33186991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
    Rentsch CT; Beckman JA; Tomlinson L; Gellad WF; Alcorn C; Kidwai-Khan F; Skanderson M; Brittain E; King JT; Ho YL; Eden S; Kundu S; Lann MF; Greevy RA; Ho PM; Heidenreich PA; Jacobson DA; Douglas IJ; Tate JP; Evans SJW; Atkins D; Justice AC; Freiberg MS
    BMJ; 2021 Feb; 372():n311. PubMed ID: 33574135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
    Tacquard C; Mansour A; Godon A; Godet J; Poissy J; Garrigue D; Kipnis E; Rym Hamada S; Mertes PM; Steib A; Ulliel-Roche M; Bouhemad B; Nguyen M; Reizine F; Gouin-Thibault I; Besse MC; Collercandy N; Mankikian S; Levy JH; Gruel Y; Albaladejo P; Susen S; Godier A;
    Chest; 2021 Jun; 159(6):2417-2427. PubMed ID: 33465342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
    Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
    Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis in COVID-19: A Narrative Review of Current Literature and Inpatient Management.
    Hsu A; Ohnigian S; Chang A; Liu Y; Zayac AS; Olszewski AJ; Reagan JL
    R I Med J (2013); 2021 Jun; 104(5):14-19. PubMed ID: 34044431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
    Ortega-Paz L; Galli M; Capodanno D; Franchi F; Rollini F; Bikdeli B; Mehran R; Montalescot G; Gibson CM; Lopes RD; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):677-686. PubMed ID: 34519777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.
    Vaughn VM; Yost M; Abshire C; Flanders SA; Paje D; Grant P; Kaatz S; Kim T; Barnes GD
    JAMA Netw Open; 2021 Jun; 4(6):e2111788. PubMed ID: 34115129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
    Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
    J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study.
    Yamashita Y; Yachi S; Takeyama M; Nishimoto Y; Tsujino I; Nakamura J; Yamamoto N; Nakata H; Ikeda S; Umetsu M; Aikawa S; Hayashi H; Satokawa H; Okuno Y; Iwata E; Ogihara Y; Ikeda N; Kondo A; Iwai T; Yamada N; Ogawa T; Kobayashi T; Mo M
    Circ J; 2022 Jun; 86(7):1137-1142. PubMed ID: 35662177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.
    Cryer MJ; Farhan S; Kaufmann CC; Jäger B; Garg A; Krishnan P; Mehran R; Huber K
    Clin Appl Thromb Hemost; 2022; 28():10760296221074353. PubMed ID: 35068227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation in hospitalized patients with COVID-19.
    Baumann Kreuziger L; Sholzberg M; Cushman M
    Blood; 2022 Aug; 140(8):809-814. PubMed ID: 35653590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.
    Piazza G; Campia U; Hurwitz S; Snyder JE; Rizzo SM; Pfeferman MB; Morrison RB; Leiva O; Fanikos J; Nauffal V; Almarzooq Z; Goldhaber SZ
    J Am Coll Cardiol; 2020 Nov; 76(18):2060-2072. PubMed ID: 33121712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19.
    Mennuni MG; Renda G; Grisafi L; Rognoni A; Colombo C; Lio V; Foglietta M; Petrilli I; Pirisi M; Spinoni E; Azzolina D; Hayden E; Aimaretti G; Avanzi GC; Bellan M; Cantaluppi V; Capponi A; Castello LM; D'Ardes D; Corte FD; Gallina S; Krengli M; Malerba M; Pierdomenico SD; Savoia P; Zeppegno P; Sainaghi PP; Cipollone F; Patti G;
    J Thromb Thrombolysis; 2021 Oct; 52(3):782-790. PubMed ID: 33649979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.